PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25990337-5	2015	Patients with ALK rearrangements treated with specific ALK inhibitors such as crizotinib or EGFR-activating mutations treated with gefitinib, erlotinib or afatinib have improved progression-free survival and better quality of life than patients treated with chemotherapy.	Erlotinib Hydrochloride	142-151	ALK receptor tyrosine kinase	Homo sapiens	14-17	
25990337-5	2015	Patients with ALK rearrangements treated with specific ALK inhibitors such as crizotinib or EGFR-activating mutations treated with gefitinib, erlotinib or afatinib have improved progression-free survival and better quality of life than patients treated with chemotherapy.	Erlotinib Hydrochloride	142-151	ALK receptor tyrosine kinase	Homo sapiens	55-58